HIV-1 Salvage Therapy Can Omit NRTIs and Remain Efficacious and Safe
People with HIV-1 infection who have virologic failure can safely omit nucleoside reverse transcriptase inhibitors (NRTIs) in new regimens that include > 2 active drugs.
People with HIV-1 infection who have virologic failure can safely omit nucleoside reverse transcriptase inhibitors (NRTIs) in new regimens that include > 2 active drugs.
Children living with HIV demonstrate deficits in bone architecture and reductions in bone strength, compared with children without HIV.
Although tenofovir alafenamide coformulated with emtricitabine has a marginally more benign side effect profile compared with tenofovir disoproxil fumarate coformulated with emtricitabine the additional cost of the newer HIV PrEP is not justifiable.
Expanding daily oral antiretroviral pre-exposure prophylaxis to persons at high risk for HIV may accelerate the reductions in new HIV diagnoses in the United States.
There is an increased need for PrEP uptake among transgender women, men who have sex with men, and transgender women of color in the United States.
Cytomegalovirus (CMV) viremia is suppressed after the start of antiretroviral treatment (ART) without specific anti-CMV treatment.
Two-drug regimens are shown to be comparable with 3-drug regimens as viable clinical treatment options for HIV.
Particular antiretroviral therapy (ART) regimens may decrease bone mass density (BMD) in both adolescents and older people living with HIV (PWHIV).
Dolutegravir (DTG) discontinuation due to neuropsychologic side effects (NPS) may be associated with pre-existing psychiatric conditions of depression and anxiety.
A long-acting therapy may be noninferior to the current daily oral antiretroviral therapy (ART) in maintaining viral suppression in the treatment of HIV-1 infection.